FINWIRES · TerminalFinancial News · Live TerminalLIVE

SHE:000661

24 stories mentioning SHE:000661Updated 9d ago

Every FINWIRES story that references SHE:000661, newest first.

What's the latest news on SHE:000661?

Changchun High-Tech Unit Gets China Approval for Osteoporosis Drug Clinical Trial

Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Jinsai Pharmaceutical received clinical trial approval from China's drug regulator for GenSci133 as an osteoporosis treatment, according to a Saturday filing with the Shenzhen bourse.The drug is indicated for subcutaneous injection every three to six months, the filing said.Shares in the drug company fell 1% during afternoon trading on Monday.

Changchun High-Tech Industry Applies for GenSci161 Clinical Trial

Changchun High-Tech Industry (SHE:000661) applied with China's drug regulator to conduct clinical trials for GenSci161 injection.The drug is intended for connective tissue disease-associated interstitial lung disease, according to a Tuesday filing with the Shenzhen bourse.Shares of the drug manufacturer rose 2% in recent trade.

Changchun High-Tech Gets Clinical Trial Green Light for Eye Drug

Changchun High-Tech Industry (SHE:000661) obtained the approval of China's drug regulator to conduct clinical trials for GenSci148 injection.The drug is intended for neovascular age-related macular degeneration, diabetic macular edema and retinal vein occlusion, which cause visual impairment, according to a Tuesday filing with the Shenzhen bourse.Shares of the drug manufacturer rose 6% in recent trade.

Changchun High-Tech Industry's Unit Gets Nod to Trial GenSci148 Injection; Shares Jump 5%

Changchun High-Tech Industry's (SHE:000661) unit, Changchun GeneScience Pharmaceutical, obtained approval from China's National Medical Products Administration for the clinical trial application of GenSci148 injection, according to a Shenzhen bourse filing on Tuesday.The drug is developed as a treatment for neovascular age-related macular degeneration, diabetic macular edema and retinal vein occlusion.The pharmaceutical company's shares jumped 5% during the afternoon trade.

China's Drug Regulator Accepts Changchun High-Tech Unit's Clinical Trial Application for GenSci133 Injection

Changchun High-Tech Industry (SHE:000661) said China's medical products regulator accepted the clinical trial application of its GenSci133 injection for osteoporosis treatment, according to a Thursday filing with the Shenzhen bourse..Shares of the pharmaceutical company were down 3% in recent trade.

Changchun High-Tech's Unit Gets Nod for GenSci144 Tablets' Trial

Changchun High-Tech Industry's (SHE:000661) unit, Changchun GeneScience Pharmaceuticals, obtained approval from China's National Medical Products Administration for the clinical trial of GenSci144 tablets, according to a Friday disclosure on the Shenzhen bourse.The product will be tested as a treatment for chronic kidney disease.

China's Drug Regulator Accepts Changchun High-Tech Unit's Clinical Trial Application for GenSci155 Injection; Shares Up 5%

China's National Medical Products Administration accepted the clinical trial application of Changchun High-Tech Industry's (SHE:000661) unit, Changchun Jinsai Pharmaceutical, for GenSci155 injection, according to a Shenzhen bourse filing on Saturday.The Chinese pharmaceutical company's shares jumped 5% during Monday's afternoon trade.The drug is being developed to be used to prevent bronchopulmonary dysplasia in premature infants.

Chinese Drug Regulator Accepts Changchun High-Tech's Clinical Trial Application for GenSci136 for Injection

China's National Medical Products Administration accepted Changchun High-Tech Industry's (SHE:000661) clinical trial application for GenSci136 for injection, according to a Shenzhen bourse filing on Friday.The drug will be tested as a treatment for systemic lupus erythematosus.

Changchun High-Tech Industry Obtains China Marketing Approval for Gastric Cancer Drug

Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Jinsai Pharmaceutical received marketing authorization from China's National Medical Products Administration for its Jintuximab Injection, according to a Wednesday filing with the Shanghai bourse.The drug is indicated in combination with paclitaxel for patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Changchun High-Tech Industry Gets China Approval for Eyelid Movement Treatment

China's drug regulator approved production of GenSci136 for injection produced by Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Jinsai Pharmaceutical.The drug is indicated for ocular myasthenia gravis, a condition that affects the movement of the muscles controlling eye movements and eyelids.

Changchun High-Tech Industry Gets China Nod for GenSci155 Trial

Changchun High-Tech Industry (SHE:000661) subsidiary GeneScience obtained China's regulatory approval to conduct clinical trials for GenSci155 injection.The drug is indicated for preventing bronchopulmonary dysplasia in premature infants and treating acute ischemic stroke, according to a Thursday filing with the Shenzhen bourse.Shares of the drug manufacturer closed 2% lower Thursday.

Changchun High-Tech Industry Gets US FDA Nod for Autoimmune Disease Drug Trial

Changchun High-Tech Industry (SHE:000661) subsidiary GeneScience received the approval of the U.S. Food and Drug Administration to start clinical trials in the U.S. for GenSci136.The drug is indicated for autoimmune disease myasthenia gravis, according to a Tuesday filing with the Shenzhen bourse.Shares of the drug manufacturer closed 2% lower Tuesday.

Changchun High-Tech Industry Gets US FDA Nod for Cancer Drug Trial

Changchun High-Tech Industry (SHE:000661) subsidiary GeneScience received approval of the U.S. Food and Drug Administration to start clinical trials in the U.S. for GenSci145 tablets.The drug is indicated for locally advanced or metastatic solid tumors with PIK3CA mutations, which occur in 30% to 40% of breast cancers, according to a Tuesday filing with the Shenzhen bourse.Shares of the drug manufacturer closed 2% lower Tuesday.

Changchun High-Tech Subsidiary Secures Chinese Regulatory Nod for Phenylketonuria Drug Clinical Trials

Changchun High-Tech Industry's (SHE:000661) subsidiary, Changchun GeneScience Pharmaceutical, received approval from China's National Medical Products Administration for the clinical trials of GenSci144 tablets, according to a Shenzhen bourse filing on Wednesday.The drug will be tested as a treatment for phenylketonuria, a genetic disorder caused by defects in the phenylalanine hydroxylase gene, leading to hyperphenylalaninemia.The Chinese drug manufacturer's shares dropped 2% during the afternoon trade.

China Accepts Changchun High-Tech Industry Subsidiary's Clinical Trial Application for Chronic Kidney Disease Tablets

China's drug regulator accepted Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Jinsai Pharmaceutical's clinical trial application for its GenSci144 tablets for chronic kidney disease, according to a Tuesday filing with the Shenzhen bourse.

Changchun High-Tech Industry Wins US FDA Nod to Start Clinical Trials for Rare Skin Disease Drug

Changchun High-Tech Industry (SHE:000661) unit Genescience obtained the U.S. Food and Drug Administration's approval to conduct clinical trials for GenSci161 injection.The drug is used to treat hidradenitis suppurativa, a chronic inflammatory skin disease, according to a weekend filing with the Shenzhen bourse.Shares of the drug manufacturer closed 2% lower Monday.

Changchun High-Tech Industry Gets China Nod for Gout Drug Trial

Changchun High-Tech Industry (SHE:000661) secured Chinese regulatory approval to begin clinical trials for fuxinqibai injection.The monoclonal antibody is indicated for reducing acute gout flares during early urate-lowering therapy, according to a Wednesday filing with the Shenzhen bourse.Shares of the drug manufacturer were down 2% in recent trade.

Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug

Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.

Changchun High-Tech Gets Approval for Clinical Trial of GenSci155

Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory acceptance for the clinical trial application of GenSci155 injection.The drug is indicated to prevent bronchopulmonary dysplasia in preterm infants and to treat acute ischemic stroke, according to a Thursday filing with the Shenzhen bourse.

Changchun High-Tech Industry's Attributable Profit Slides 42% in Q1

Changchun High-Tech Industry's (SHE:000661) attributable profit fell 42% to 275.7 million yuan in the first quarter from 472.7 million yuan in the year-ago period, according to a Wednesday filing with the Shenzhen bourse.Earnings per share at the drug manufacturer decreased to 0.69 yuan from 1.17 yuan in the prior-year period.Operating income declined 14% year over year to 2.59 billion yuan from 3 billion yuan.

Showing 1-20 of 24

Track with the FINWIRES app suite

Track SHE:000661 in your portfolio

Analyze SHE:000661 options with the wheel strategy

See market sentiment on SHE:000661